BR0308936A - interações da proteìna da pancortina - pablo e métodos de uso das mesmas - Google Patents

interações da proteìna da pancortina - pablo e métodos de uso das mesmas

Info

Publication number
BR0308936A
BR0308936A BRPI0308936-3A BR0308936A BR0308936A BR 0308936 A BR0308936 A BR 0308936A BR 0308936 A BR0308936 A BR 0308936A BR 0308936 A BR0308936 A BR 0308936A
Authority
BR
Brazil
Prior art keywords
pancortin
pablo
polypeptides
interaction
methods
Prior art date
Application number
BRPI0308936-3A
Other languages
English (en)
Inventor
Robert John Mark
Andrew Timothy Wood
Kamalakar Gulukota
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0308936A publication Critical patent/BR0308936A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"INTERAçõES DA PROTEìNA DA PANCORTINA PABLO E MéTODOS DE USO DAS MESMAS". Esta invenção refere-se a polipeptídeos da pancortina humana recentemente identificados, a interação dos polipeptídeos da pancortina com um polipeptídeo pablo, o uso destes polipeptídeos, assim como a produção destes polipeptídeos. A invenção também se refere à identificação de compostos que modulam a atividade de polipeptídeos da pancortina e/ou a interação de uma interação pancortina - polipeptídeo pablo, em que os moduladores podem ser agonistas, antagonistas e/ou inibidores de pancortina e/ou a interação pancortina /pablo e, assim, potencialmente utilizáveis em terapia.
BRPI0308936-3A 2002-04-01 2003-03-27 interações da proteìna da pancortina - pablo e métodos de uso das mesmas BR0308936A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36924402P 2002-04-01 2002-04-01
US38664502P 2002-06-06 2002-06-06
PCT/US2003/009572 WO2003085377A2 (en) 2002-04-01 2003-03-27 Novel pancortin-pablo protein interactions and methods of use thereof

Publications (1)

Publication Number Publication Date
BR0308936A true BR0308936A (pt) 2007-01-30

Family

ID=28794347

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308936-3A BR0308936A (pt) 2002-04-01 2003-03-27 interações da proteìna da pancortina - pablo e métodos de uso das mesmas

Country Status (9)

Country Link
US (1) US20030215852A1 (pt)
EP (1) EP1501857A4 (pt)
JP (1) JP2005521424A (pt)
CN (1) CN1656114A (pt)
AU (1) AU2003260487A1 (pt)
BR (1) BR0308936A (pt)
CA (1) CA2481090A1 (pt)
MX (1) MXPA04009510A (pt)
WO (1) WO2003085377A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157327A1 (en) * 1999-10-22 2004-08-12 Wyeth Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto
CN105950654B (zh) * 2010-11-27 2020-03-20 朱坚 一种人源化的转基因动物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656470A (en) * 1994-09-13 1997-08-12 Cubist Pharmaceuticals, Inc. Recombinant mycobacterial seryl-tRNA synthetase genes, tester strains and assays
US6183968B1 (en) * 1998-03-27 2001-02-06 Incyte Pharmaceuticals, Inc. Composition for the detection of genes encoding receptors and proteins associated with cell proliferation
US6183969B1 (en) * 1999-04-15 2001-02-06 Rutgers, The State University Of New Jersey Intron-based assay for detecting and characterizing chromosomal rearrangement
JP2003515319A (ja) * 1999-10-22 2003-05-07 ワイス パブロ、すなわちＢｃｌ−ｘＬと相互作用するポリペプチド、およびそれに関連する使用
PL358580A1 (en) * 2000-04-27 2004-08-09 Smithkline Beecham Corporation Novel compounds
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
WO2002006339A2 (en) * 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
EP1478772A2 (en) * 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA

Also Published As

Publication number Publication date
EP1501857A4 (en) 2005-11-16
WO2003085377A2 (en) 2003-10-16
WO2003085377A3 (en) 2004-12-02
MXPA04009510A (es) 2005-01-25
CN1656114A (zh) 2005-08-17
US20030215852A1 (en) 2003-11-20
AU2003260487A1 (en) 2003-10-20
AU2003260487A8 (en) 2003-10-20
EP1501857A2 (en) 2005-02-02
CA2481090A1 (en) 2003-10-16
JP2005521424A (ja) 2005-07-21

Similar Documents

Publication Publication Date Title
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR0316502A (pt) Compostos quìmicos
BRPI0411020A (pt) perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição
TW200607814A (en) Cell surface receptor isoforms and methods of identifying and using the same
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
ATE496636T1 (de) Verwendung von agonisten und antagonisten von interleukin-33 (il-33)
AR063149A1 (es) Formulaciones a base de polipeptidos estables
BR9814956A (pt) Inibidores de benzotiazol da tirosina cinase de proteìna
PL377553A1 (pl) Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
BRPI0507776A (pt) métodos de modular a atividade de citocina; reagentes relacionados
AR061245A1 (es) Composiciones y metodos para la modulacion del desarrollo vascular
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
BRPI0409916A (pt) ácidos carboxìlicos substituìdos com fenila
BRPI0611964A2 (pt) moduladores de alquilquinolina e alquilquinazolina cinase
HUP0002427A2 (hu) Leptin mint tumorsejt proliferációt gátló hatóanyag és alkalmazása
BR0303482A (pt) Aparelho para uso no controle e/ou nos testes de um sistema de produção de hidrocarboneto
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
NO20014417L (no) Vaskul¶re adhesjonsmolekyler samt modulering av deres funksjon
BR112015019729A2 (pt) composição inibidora da il-1b e uso da mesma
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22